Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: Effects on pharmacokinetics, pharmacodynamics, and clinical outcomes

Matthew J. Labreche, Chris Frei

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose. Published evidence of rising gram-negative bacterial resistance to fluoroquinolone therapy is reviewed, with a focus on the potential need for revising pharmacokinetic-pharmacodynamic (PK-PD) targets in order to maintain acceptable clinical outcomes. Summary. With a more than threefold increase in fluoroquinolone use among U.S. adults since the introduction of second- and third-generation (i.e., "respiratory") fluoroquinolones 15 years ago, surveillance data indicate a decline in some gram-negative organisms' susceptibility to this antimicrobial class. These trends have raised concerns that the need to attain higher organism-specific minimum inhibitory concentrations (MICs) may lead to worse patient outcomes, even when MIC values are below current established "clinical breakpoints" for fluoroquinolone susceptibility. A growing body of evidence from PK-PD studies suggests that current fluoroquinolone dosing regimens are no longer adequate to achieve validated PK-PD targets. For example, a Monte Carlo simulation using PK data from U.S. hospitals showed decreasing rates of response to standard ciprofloxacin and levofloxacin i.v. dosing regimens among patients treated for infections with Escherichia coli and Klebsiella species. These findings suggest that currently accepted PK-PD targets may need to be revised for certain patient populations, including patients with bloodstream infections (BSIs). More research is needed to confirm the appropriateness of adjusting clinical breakpoints and other strategies to combat rising fluoroquinolone resistance. Conclusion. The use of the fluoroquinolones has markedly increased since the introduction of the respiratory fluoroquinolones. Surveillance data and PK-PD studies have raised concerns about suboptimal patient outcomes with the use of fluoroquinolones for some gram-negative infections, particularly BSIs. PK-PD goals and clinical breakpoints may need to be revised for these infections.

Original languageEnglish (US)
Pages (from-to)1863-1870
Number of pages8
JournalAmerican Journal of Health-System Pharmacy
Volume69
Issue number21
DOIs
StatePublished - Nov 1 2012

Fingerprint

Fluoroquinolones
Gram-Negative Bacteria
Pharmacokinetics
Microbial Sensitivity Tests
Infection
Escherichia coli Infections
Levofloxacin
Klebsiella
Ciprofloxacin

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy

Cite this

Declining susceptibilities of gram-negative bacteria to the fluoroquinolones : Effects on pharmacokinetics, pharmacodynamics, and clinical outcomes. / Labreche, Matthew J.; Frei, Chris.

In: American Journal of Health-System Pharmacy, Vol. 69, No. 21, 01.11.2012, p. 1863-1870.

Research output: Contribution to journalArticle

@article{5b1cf8226dae4b64be8c983475c237c6,
title = "Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: Effects on pharmacokinetics, pharmacodynamics, and clinical outcomes",
abstract = "Purpose. Published evidence of rising gram-negative bacterial resistance to fluoroquinolone therapy is reviewed, with a focus on the potential need for revising pharmacokinetic-pharmacodynamic (PK-PD) targets in order to maintain acceptable clinical outcomes. Summary. With a more than threefold increase in fluoroquinolone use among U.S. adults since the introduction of second- and third-generation (i.e., {"}respiratory{"}) fluoroquinolones 15 years ago, surveillance data indicate a decline in some gram-negative organisms' susceptibility to this antimicrobial class. These trends have raised concerns that the need to attain higher organism-specific minimum inhibitory concentrations (MICs) may lead to worse patient outcomes, even when MIC values are below current established {"}clinical breakpoints{"} for fluoroquinolone susceptibility. A growing body of evidence from PK-PD studies suggests that current fluoroquinolone dosing regimens are no longer adequate to achieve validated PK-PD targets. For example, a Monte Carlo simulation using PK data from U.S. hospitals showed decreasing rates of response to standard ciprofloxacin and levofloxacin i.v. dosing regimens among patients treated for infections with Escherichia coli and Klebsiella species. These findings suggest that currently accepted PK-PD targets may need to be revised for certain patient populations, including patients with bloodstream infections (BSIs). More research is needed to confirm the appropriateness of adjusting clinical breakpoints and other strategies to combat rising fluoroquinolone resistance. Conclusion. The use of the fluoroquinolones has markedly increased since the introduction of the respiratory fluoroquinolones. Surveillance data and PK-PD studies have raised concerns about suboptimal patient outcomes with the use of fluoroquinolones for some gram-negative infections, particularly BSIs. PK-PD goals and clinical breakpoints may need to be revised for these infections.",
author = "Labreche, {Matthew J.} and Chris Frei",
year = "2012",
month = "11",
day = "1",
doi = "10.2146/ajhp110464",
language = "English (US)",
volume = "69",
pages = "1863--1870",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "21",

}

TY - JOUR

T1 - Declining susceptibilities of gram-negative bacteria to the fluoroquinolones

T2 - Effects on pharmacokinetics, pharmacodynamics, and clinical outcomes

AU - Labreche, Matthew J.

AU - Frei, Chris

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Purpose. Published evidence of rising gram-negative bacterial resistance to fluoroquinolone therapy is reviewed, with a focus on the potential need for revising pharmacokinetic-pharmacodynamic (PK-PD) targets in order to maintain acceptable clinical outcomes. Summary. With a more than threefold increase in fluoroquinolone use among U.S. adults since the introduction of second- and third-generation (i.e., "respiratory") fluoroquinolones 15 years ago, surveillance data indicate a decline in some gram-negative organisms' susceptibility to this antimicrobial class. These trends have raised concerns that the need to attain higher organism-specific minimum inhibitory concentrations (MICs) may lead to worse patient outcomes, even when MIC values are below current established "clinical breakpoints" for fluoroquinolone susceptibility. A growing body of evidence from PK-PD studies suggests that current fluoroquinolone dosing regimens are no longer adequate to achieve validated PK-PD targets. For example, a Monte Carlo simulation using PK data from U.S. hospitals showed decreasing rates of response to standard ciprofloxacin and levofloxacin i.v. dosing regimens among patients treated for infections with Escherichia coli and Klebsiella species. These findings suggest that currently accepted PK-PD targets may need to be revised for certain patient populations, including patients with bloodstream infections (BSIs). More research is needed to confirm the appropriateness of adjusting clinical breakpoints and other strategies to combat rising fluoroquinolone resistance. Conclusion. The use of the fluoroquinolones has markedly increased since the introduction of the respiratory fluoroquinolones. Surveillance data and PK-PD studies have raised concerns about suboptimal patient outcomes with the use of fluoroquinolones for some gram-negative infections, particularly BSIs. PK-PD goals and clinical breakpoints may need to be revised for these infections.

AB - Purpose. Published evidence of rising gram-negative bacterial resistance to fluoroquinolone therapy is reviewed, with a focus on the potential need for revising pharmacokinetic-pharmacodynamic (PK-PD) targets in order to maintain acceptable clinical outcomes. Summary. With a more than threefold increase in fluoroquinolone use among U.S. adults since the introduction of second- and third-generation (i.e., "respiratory") fluoroquinolones 15 years ago, surveillance data indicate a decline in some gram-negative organisms' susceptibility to this antimicrobial class. These trends have raised concerns that the need to attain higher organism-specific minimum inhibitory concentrations (MICs) may lead to worse patient outcomes, even when MIC values are below current established "clinical breakpoints" for fluoroquinolone susceptibility. A growing body of evidence from PK-PD studies suggests that current fluoroquinolone dosing regimens are no longer adequate to achieve validated PK-PD targets. For example, a Monte Carlo simulation using PK data from U.S. hospitals showed decreasing rates of response to standard ciprofloxacin and levofloxacin i.v. dosing regimens among patients treated for infections with Escherichia coli and Klebsiella species. These findings suggest that currently accepted PK-PD targets may need to be revised for certain patient populations, including patients with bloodstream infections (BSIs). More research is needed to confirm the appropriateness of adjusting clinical breakpoints and other strategies to combat rising fluoroquinolone resistance. Conclusion. The use of the fluoroquinolones has markedly increased since the introduction of the respiratory fluoroquinolones. Surveillance data and PK-PD studies have raised concerns about suboptimal patient outcomes with the use of fluoroquinolones for some gram-negative infections, particularly BSIs. PK-PD goals and clinical breakpoints may need to be revised for these infections.

UR - http://www.scopus.com/inward/record.url?scp=84868603184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868603184&partnerID=8YFLogxK

U2 - 10.2146/ajhp110464

DO - 10.2146/ajhp110464

M3 - Article

C2 - 23111670

AN - SCOPUS:84868603184

VL - 69

SP - 1863

EP - 1870

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 21

ER -